He is also a member of the Huntsman Cancer Institute Experimental Therapeutics Program and the Nano-Institute of Utah. Prior to his position in Utah, he was a Postdoctoral Fellow at the University of Toronto. Current research in his lab focuses on evaluating the pharmaceutic stability of antibody-based therapeutics, creating ADCs that induce self-amplifying therapeutic cascades, and engineering antibody-split enzyme systems for diagnostic applications.